{"id":"NCT00735371","sponsor":"Shire","briefTitle":"Efficacy and Safety of Lisdexamfetamine Dimesylate (LDX) in Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD)","officialTitle":"A Phase III, Randomized, Double-Blind, Multi-Center, Parallel-Group, Placebo-Controlled, Forced-dose Titration, Safety and Efficacy Study of Lisdexamfetamine Dimesylate (LDX) in Adolescents Aged 13-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-10-08","primaryCompletion":"2009-04-06","completion":"2009-04-06","firstPosted":"2008-08-14","resultsPosted":"2010-02-23","lastUpdate":"2021-06-14"},"enrollment":314,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Attention Deficit Hyperactivity Disorder (ADHD)"],"interventions":[{"type":"DRUG","name":"LDX 30 mg","otherNames":["Vyvanse"]},{"type":"DRUG","name":"LDX 50 mg","otherNames":[]},{"type":"DRUG","name":"LDX 70 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Lisdexamfetamine Dimesylate (LDX) 30 mg","type":"ACTIVE_COMPARATOR"},{"label":"LDX 50 mg","type":"ACTIVE_COMPARATOR"},{"label":"LDX 70 mg","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The study will evaluate the efficacy of LDX treatment group compared to placebo on the change from Baseline ADHD-RS-IV score at endpoint.","primaryOutcome":{"measure":"Change From Baseline in Attention Deficit Hyperactivity Disorder Rating Scale-fourth Edition (ADHD-RS-IV) Total Score at up to 4 Weeks","timeFrame":"Baseline and 1, 2, 3 and 4 weeks","effectByArm":[{"arm":"Lisdexamfetamine Dimesylate (LDX) 30 mg","deltaMin":-18.3,"sd":1.25},{"arm":"LDX 50 mg","deltaMin":-21.1,"sd":1.28},{"arm":"LDX 70 mg","deltaMin":-20.7,"sd":1.25},{"arm":"Placebo","deltaMin":-12.8,"sd":1.25}],"pValues":[{"comp":"OG000 vs OG003","p":"0.0056"},{"comp":"OG001 vs OG003","p":"<0.0001"},{"comp":"OG002 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"13 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":45,"countries":["United States"]},"refs":{"pmids":["21421179"],"seeAlso":["http://www.fda.gov/opacom/7alerts.html"]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":78},"commonTop":["Decreased appetite","Headache","Insomnia","Weight decreased","Irritability"]}}